Alagille Syndrome Market to Grow Positively at a Paltry CAGR During the Study Period | Albireo, and other companies are expected to boost the market

DelveInsight's "Alagille Syndrome - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Alagille Syndrome market share of the individual therapies, current and forecasted Alagille Syndrome market size from 2019 to 2032 segmented by seven major markets. The report also offers current Alagille Syndrome therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Alagille Syndrome market.
Download sample pages @ https://www.delveinsight.com/report-store/alagille-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the alagille syndrome market report:
The Alagille Syndrome market is projected to grow based on various factors, such as increasing awareness, advancements in diagnostic technologies, and the introduction of novel treatment options for the condition.
DelveInsight's analysts estimated that there had been an increase in Alagille syndrome occurrences in recent years, which may be attributed to factors such as improved awareness or diagnostic advancements.
Companies such as Ipsen, Takeda, and others have emerged as key players in the market, taking the lead in developing their respective assets for the treatment of Alagille Syndrome. With the anticipated launch of these therapies between 2023 and 2032, the overall Alagille Syndrome therapeutic market is expected to experience substantial growth at a significant compound annual growth rate (CAGR).
Alagille Syndrome Overview
Alagille syndrome, also known as Alagille-Watson syndrome or arteriohepatic dysplasia, is a rare genetic disorder that primarily affects the liver and other organs. It is caused by mutations in the JAG1 or NOTCH2 genes, which play a crucial role in the development of various organs and tissues during embryonic development. The liver, heart, eyes, and kidneys are often affected in Alagille syndrome. Due to its impact on multiple organs, Alagille syndrome typically requires a multidisciplinary approach, involving specialists in cardiac interventions, liver-related complications, growth and development, eye abnormalities, and supportive care, including genetic counseling.

Diagnosing Alagille syndrome involves a combination of clinical evaluation, assessment of symptoms, and genetic testing to identify mutations in the JAG1 or NOTCH2 genes. Imaging studies such as ultrasound, echocardiogram, and liver biopsy may also be performed to evaluate the extent of organ involvement. The diverse and variable clinical presentation of Alagille syndrome can pose significant challenges in diagnosis.

Treatment for Alagille syndrome is generally focused on managing the specific symptoms and complications that arise. This may involve medication to alleviate itching, surgical interventions to address heart defects or bile duct abnormalities, dietary modifications to ensure adequate nutrition, and regular monitoring of liver function.

Treating Alagille syndrome presents several challenges due to the involvement of multiple organs and the variability in symptom severity among patients. A primary challenge is the scarcity of tailored therapies that specifically address the unique characteristics of Alagille syndrome.

To know more about alagille syndrome, visit: https://www.delveinsight.com/report-store/alagille-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Alagille Syndrome Epidemiological Insights
As per the estimates by DelveInsight, the total cases of Alagille syndrome in the 7MM were around 18,000 cases in 2022.
In 2022, among EU4 and the UK, Germany accounted for the highest number of cases, followed by France, according to estimates by DelveInsight.
According to Diaz et al. (2019), it is estimated that the prevalence of Alagille syndrome varies from 1:30,000 to 1:100,000.
In 2022, there was about a 4:3 ratio of males and females diagnosed with ALGS in the United States. Assessments, as per DelveInsight's analysts, show that the overall prevalence of gender cases of ALGS will increase in the coming years by 2032.

Alagille Syndrome Treatment Market
The current treatment for Alagille Syndrome involves a comprehensive approach that includes managing liver-related complications through medications to improve bile flow and liver function, interventions for cardiac defects if present, monitoring and support for growth and development, regular eye examinations for any associated abnormalities, and the provision of supportive care and genetic counseling to address the overall well-being of individuals with Alagille Syndrome. LIVMARLI and BYLVAY have recently received approval for treating Alagille Syndrome.

Ongoing research and development efforts focused on identifying novel therapeutic interventions and genetic targets hold promise for developing innovative treatment options. The advent of precision medicine and personalized therapies tailored to an individual's genetic profile further adds to the market's potential growth. Collaborative efforts between pharmaceutical companies, research institutions, and advocacy groups will likely drive investment and support for Alagille Syndrome research and development.

Marketed Alagille Syndrome Drugs

LIVMARLI (maralixibat): Mirum Pharmaceuticals

In September 2021, FDA-approved LIVMARLI (maralixibat) to treat cholestatic pruritus associated with Alagille syndrome. In September 2022, LIVMARLI was approved for the same in the European Union. It is an oral solution designed for daily use that acts as an inhibitor of the ileal bile acid transporter (IBAT) and is the only medication approved in both the US and Europe for the treatment of cholestatic pruritus specifically associated with Alagille syndrome.

In September 2021, Mirum and Takeda entered into an exclusive licensing agreement to develop and commercialize maralixibat in Japan.

In December 2022, Takeda received Orphan Drug Designation from the Ministry of Health, Labour, and Welfare for Maralixibat chloride (TAK-625) for the expected indication of Alagille syndrome (ALGS)

BYLVAY (odevixibat): Ipsen/Albireo

In June 2023, Ipsen received US FDA approval for BYLVAY (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome. It is a once-a-day, non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally in the small intestine and has minimal systemic exposure. Ipsen picked up this drug in its January 2023 acquisition of Albireo.

Promising Therapies in the Alagille Syndrome Pipeline
Odevixibat
And others
Discover more about Alagille Syndrome therapies in the pipeline @ https://www.delveinsight.com/sample-request/alagille-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Alagille Syndrome Market
Albireo
And others
To understand key companies related to the Alagille Syndrome Market, get a snapshot of the Alagille Syndrome Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/alagille-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Alagille Syndrome Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Alagille Syndrome Companies: Albireo, and others
Key Alagille Syndrome Pipeline Therapies: Odevixibat, and others
Therapeutic Assessment: Alagille Syndrome current marketed and emerging therapies
Alagille Syndrome Market Dynamics: Alagille Syndrome market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Alagille Syndrome Market Access and Reimbursement
Table of Contents
1. Alagille Syndrome Market Key Insights
2. Alagille Syndrome Market Report Introduction
3. Alagille Syndrome Market Overview at a Glance
4. Alagille Syndrome Market Executive Summary
5. Disease Background and Overview
6. Alagille Syndrome Treatment and Management
7. Alagille Syndrome Epidemiology and Patient Population
8. Patient Journey
9. Alagille Syndrome Emerging Drugs
10. 7MM Alagille Syndrome Market Analysis
11. Alagille Syndrome Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Alagille Syndrome Market Drivers
15. Alagille Syndrome Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.